InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Roundtable: The second medical use challenge – full transcript

James Nurton, London


Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London

This is the full, unabridged, transcript of the discussion, which was held on January 18 this year at the office of Bristows in London, and was moderated by Managing IP’s James Nurton. The views expressed are those of the participants...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

John Bochnovic, Executive Director of AIPPI, has resigned from the position (effective April 30, 2018) to return to… https://t.co/4dp8lsqg5Z

Feb 16 2018 04:19 ·  reply ·  retweet ·  favourite
ManagingIP profile

CAFC says 101 inquiry is a factual determination in “blockbuster” Berkheimer opinion https://t.co/wpYscoUhnY https://t.co/FPrkImTmGL

Feb 16 2018 03:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

US falls to 12th in US Chamber patent ranking https://t.co/UP7AvAbZ4k Expect to hear this figure mentioned a lot at… https://t.co/gnWLDdISl2

Feb 15 2018 04:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

February 2018

FRAND aid: Is the European Commission’s SEP guidance useful?

Both patent owners and implementers have welcomed the European Commission’s communication on standard essential patents. Does that mean it has successfully balanced competing interests or merely dodged the difficult questions? James Nurton investigates



Most read articles

Supplements